Shilpa Medicare Reports FY26 Audited Results and Recommends Dividend

Shilpa Medicare Limited announced its audited financial results for the fiscal year ending March 31, 2026. The company's Board of Directors reviewed and approved both standalone and consolidated financial statements for the period.

Final Dividend Recommended

The company declared its full fiscal year audited financial results. A final dividend of Re. 0.60 per equity share for the fiscal year 2025-26 has been recommended. This payout is subject to shareholder approval at the upcoming Annual General Meeting.

Shareholder Value and Audit Assurance

Shareholders can anticipate a dividend distribution, which signifies a portion of the company's profits being returned. The audited financial statements received a clean opinion, offering assurance on Shilpa Medicare's financial reporting accuracy.

About Shilpa Medicare

Shilpa Medicare operates in the pharmaceutical sector, specializing in the manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms.

Investor Clarity for FY26

With the audited results now available and the dividend recommended, investors have clear insight into the company's financial performance and planned profit distribution for FY26.

No New Risks Highlighted

No specific risks or concerns related to the financial results were mentioned following the board meeting.

Key Financial Metrics

• Fiscal Year End: March 31, 2026
• Recommended Final Dividend: Re. 0.60 per equity share for FY 2025-26.

Next Steps for Shareholders

Shareholders should monitor the Annual General Meeting, where the dividend recommendation will be voted upon. Future financial performance and developments in the company's product pipeline will also be important areas to track.